Business Wire

CareDx Advances Global Transplant Patient Care at ESOT Congress 2023

14.9.2023 09:00:00 EEST | Business Wire | Press release

Share

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.

The latest scientific advances in global transplantation using CareDx’s AlloSeq cfDNA testing solutions are being showcased across eleven abstracts, including four posters, two moderated e-posters, one focus group, and five oral presentations. CareDx is hosting an educational symposium for medical professionals demonstrating the clinical utility of AlloSeq cfDNA. AlloSeq cfDNA is offered to European and other customers outside of the United States, to detect donor-derived cell-free DNA (dd-cfDNA) for the surveillance of allograft rejection risk in solid organ transplant patients.

“We are proud to attend ESOT Congress 2023, a preeminent European transplant conference, and share the latest data demonstrating the use of AlloSeq cfDNA,” said Reg Seeto, CEO and President of CareDx. “Through our partners and work with transplant centers internationally, we have made excellent progress in improving access to AlloSeq cfDNA for the benefit of organ transplant patients globally.”

AlloSeq cfDNA data being presented at ESOT Congress 2023

Abstract Title

KIDNEY

  • The EVACADE study: dd-cfDNA for diagnosis of acute rejection in kidney transplantation
  • Donor-derived cell-free DNA identifies “troubled” kidney allografts
  • Assessment of dd-cfDNA in kidney transplantation as a marker of graft injury - a prospective study
  • Assessment of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients with indication biopsy (selected for “Best of ESOT 2023”)
  • Impact of donor-derived cell-free DNA assessment in monitoring kidney transplant recipients: interim report of a prospective longitudinal study
  • Evolution of dd-cfDNA during the first week after surgery predicts medium to long term renal outcomes
  • Initial experience with local laboratory run assay to detect donor-derived cell-free DNA for non-invasive diagnosis of acute myocardial rejection

HEART

  • Local laboratory-run donor-derived cell-free DNA testing in stable heart transplantation: two-centre European feasibility study
  • Comparison of plasma donor-derived cell-free DNA with LASHA scoring system in lung transplantation: a single centre experience (selected for “ESOT award 2023”)

LUNG

  • Clinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation

MULTI-ORGAN

  • Multi-centric analytical performance validation of an IVD assay to quantify donor-derived cell-free DNA for solid organ transplant surveillance

“It is gratifying seeing the impact of dd-cfDNA on clinical practice and patient care. We’ve seen how the information from AlloSeq cfDNA testing not only helps clinicians in their decision-making, but also empowers transplant recipients, providing them control, understanding, and greater peace of mind on the status of their transplanted organ,” Dr. Thomas Schachtner, Transplant Specialist, University Hospital Zurich, Switzerland.

CareDx will review the latest data on AlloSeq cfDNA during an ESOT Congress 2023 Industry Satellite Symposium titled, “Adopting dd-cfDNA for Solid Organ Surveillance: Raising the Standards of Transplant Care.” The symposium will be held live and streamed virtually on ESOT’s Congress platform on Sunday, September 17, 2023. Dr. Titte Srinivas, Chief Medical Officer at CareDx and Dr. Georg Böhmig, Associate Professor at the Medical University Vienna, Austria, will moderate the session. Speakers include:

  • Maarten Naesens, MD, PhD, Clinical Director, Professor of Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium
  • Alexandre Loupy, MD, PhD, Professor of Nephrology and Epidemiology, Necker Hospital, PITOR (Paris Institute for Transplantation & Organ Regeneration), France
  • David Cucchiari, MD, PhD, Associate Professor of Nephrology, Hospital Clínic Barcelona, Catalonia, Spain

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, and with a European headquarter office in Stockholm, Sweden, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with the Company’s AlloSeq cfDNA solutions and its participation at the 2023 ESOT Congress. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its AlloSeq cfDNA solutions, or its participation at the 2023 ESOT Congress; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023, the quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed by CareDx with the SEC on May 10, 2023, the quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed by CareDx with the SEC on August 8, 2023, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CareDx, Inc.

Media Relations
Anna Czene
818-731-2203
aczene@caredx.com

Investor Relations
Greg Chodaczek
investor@caredx.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xtep-Sponsored Chinese Teenage Dancer Claims World Championship at Juste Debout Street Dance World Finals10.3.2026 20:46:00 EET | Press release

Xtep, a well-known sportswear brand from China, proudly announced that Xtep-sponsored Chinese teenage dancers delivered an electrifying performance at the Juste Debout Street Dance World Finals in Paris on Sunday, March 8, 2026, claiming top honors and showcasing a unique fusion of traditional Chinese culture with modern street dance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310519224/en/ Chinese Teens Dance to Glory at Juste Debout World Finals Li Yongqiu, a 14-year-old from Southwestern China’s Chongqing Municipality, made history by winning the Global Championship in the Junior Dance Tour, becoming the third Chinese dancer to achieve this feat. His explosive power and technical mastery, honed through years of training that integrates Kungfu elements, captivated judges and audiences alike. The Chinese contingent's success didn't stop there. Zhang Xinlan and Zhang Chuyi secured a Top 8 finish in the Popping Adult D

ATLAS Infrastructure Invests in H2O America, Backs Long-Term Growth Strategy10.3.2026 19:29:00 EET | Press release

ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing funds on behalf of long-term infrastructure clients. Following the recent equity placement, ATLAS’s actively managed accounts hold ~10.8% voting and economic interest in H2O America (“H2O”). ATLAS was pleased to support H2Os long‑term strategy to invest in local water and wastewater utility operations through our participation in the recent equity raise. ATLAS recognises the disciplined approach from H2O management which focuses on organic investment in existing businesses alongside targeted and accretive transactions such as the acquisition of Quadvest which materially expands H2O’s regulated water footprint in a premium high‑growth jurisdiction. The upsized equity raise, anchored by ATLAS, supports the company strategy through providing significant balance sheet capacity and financial flexibility well into the Company’s 2026-2030 CapEx plan. “Increased investment in water utilities is essent

Svante and Integrated Packaging Company Advance U.S. Biogenic CDR Project to Feasibility10.3.2026 15:57:00 EET | Press release

Svante Technologies Inc. (“Svante”) announced today that its bioenergy with carbon capture and storage (BECCS) project at a paper mill in the Southeast U.S. has progressed to the feasibility study phase. The project is being developed in partnership with an integrated sustainable packaging company, following an extensive screening and pre-feasibility study conducted across several of the partner’s mills. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310319382/en/ During the feasibility study phase, the companies will complete further engineering and design activities, cost and schedule estimates, and risk assessments required to evaluate commercial viability ahead of a future engineering study leading to final investment decision (FID). Svante’s subsidiary, Svante Development Inc., is co-investing in this phase with the mill owner. The project is designed to capture and permanently store more than 500,000 tonnes per year

Forbes 40th Annual World’s Billionaires List10.3.2026 15:43:00 EET | Press release

Forbes releases its 40th-annual World’s Billionaireslist, the definitive ranking of the planet’s richest people. Wealth surged to unprecedented levels over the past year, with fortunes climbing at a record pace. This year’s list features 3,428 billionaires, the most since the list’s inception in 1987. The world’s wealthiest people are worth a record $20.1 trillion combined, up from $16.1 trillion in 2025. Elon Musktops the Billionaires list for the second year in a row and is the richest person ever recorded, worth an estimated $839 billion. His net worth skyrocketed by half of a trillion dollars from last year, thanks to a rise in the value of Tesla, and SpaceX which is aiming to go public in 2026. Musk is the first person ever recorded to reach the $800 billion mark, as he moves toward becoming the world’s first trillionaire. “It’s the year of the billionaire,” said Chase Peterson-Withorn, Forbes Senior Editor, Wealth. “The planet added more than one billionaire per day over the past

Andersen Global Expands African Presence with Addition of Bravura10.3.2026 15:30:00 EET | Press release

Andersen Global strengthens its presence in Africa through a Collaboration Agreement with Bravura, a leading independent tax and financial advisory firm based in South Africa and Namibia. Founded in 1999, Bravura provides tax and financial advisory solutions to listed and private companies, entrepreneurs, and high-net-worth families across the region. Bravura combines deep financial expertise with an entrepreneurial mindset to deliver tailored strategies that drive value. The firm’s multidisciplinary team provides advisory services in mergers and acquisitions, capital raising, corporate restructuring, and succession planning. Additionally, the firm offers tax and accounting strategy, international tax structuring, global mobility, and exchange control compliance solutions. “At Bravura, we’re driven to redefine standards and deliver bespoke, results-driven solutions that create lasting value for our clients,” said Ian Matthews, head of business development at Bravura. “Our collaboration

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye